Mitchel is a reporter for MDedge based in the Philadelphia area. He started with the company in 1992, when it was International Medical News Group (IMNG), and has since covered a range of medical specialties. Mitchel trained as a virologist at Roswell Park Memorial Institute in Buffalo, and then worked briefly as a researcher at Boston Children's Hospital before pivoting to journalism as a AAAS Mass Media Fellow in 1980. His first reporting job was with Science Digest magazine, and from the mid-1980s to early-1990s he was a reporter with Medical World News. @mitchelzoler
News
Aldosterone-driven hypertension found with unexpected frequency
- Author:
- Mitchel L. Zoler, PhD
Conventionally defined primary aldosteronism occurred in roughly 20% of hypertensives, but even more showed...
News
Medicare will offer a $35/month insulin-cost cap in 2021
- Author:
- Mitchel L. Zoler, PhD
Medicare beneficiaries will have an option to select 2021 drug coverage with a $35/month cap on their out-of-...
News
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
- Author:
- Mitchel L. Zoler, PhD
Multiple factors helped keep the anticipated COVID-19 surge manageable at the hematologic oncology service of Levine Cancer Institute.
News
Leadless pacemaker shown safe in older, sicker patients
- Author:
- Mitchel L. Zoler, PhD
A large cohort receiving Micra leadless pacemakers had low complication rates in Medicare patients with frequent...
News
Polygenic risk score helps target AAA screening
- Author:
- Mitchel L. Zoler, PhD
Researchers validated a 29-item genetic risk score that improved abdominal aortic aneurysm screening pick-up when added to sex and age.
News
Many hydroxychloroquine COVID-19 prophylaxis trials lack ECG screening
- Author:
- Mitchel L. Zoler, PhD
Posted designs for trial assessing hydroxychloroquine as COVID-19 prophylaxis lack ECG-based safety screening...
News
Onyx stent meets DAPT performance goal in bleeding-risk patients
- Author:
- Mitchel L. Zoler, PhD
A zotarolimus-eluting coronary stent met its FDA-set performance goal in high-bleeding-risk patients on dual antiplatelet therapy for 1 month.
News
Silent brain infarcts found in 3% of AFib patients, tied to cognitive decline
- Author:
- Mitchel L. Zoler, PhD
MR-detected brain infarcts often developed in AFib patients on oral anticoagulation and in the absence of a...
News
UNTOUCHED: Inappropriate shocks cut by subcutaneous ICD improvements
- Author:
- Mitchel L. Zoler, PhD
Tweaking the filtering and programing of a subcutaneous ICD cut the inappropriate-shock rate in a classic ICD patient population.
News
Coffee drinking linked with fewer arrhythmias
- Author:
- Mitchel L. Zoler, PhD
Data from nearly 300,000 U.K. residents showed a statistically significant 3% drop in cardiac arrhythmias per...
News
FOURIER: Evolocumab follow-up shows no cognitive adverse effects
- Author:
- Mitchel L. Zoler, PhD
A cognition survey of more than 22,000 FOURIER patients showed no compromise linked to evolocumab or sharply cut LDL-C levels.
News
Hydroxychloroquine-triggered QTc-interval prolongations mount in COVID-19 patients
- Author:
- Mitchel L. Zoler, PhD
Two single-center reports further documented the incidence of QTc-interval prolongations in COVID-19 patients...
News
REPLENISH: Oral estradiol/progesterone slowed bone turnover as it cut VMS
- Author:
- Mitchel L. Zoler, PhD
A U.S. approved oral estradiol/progesterone formulation for treating vasomotor symptoms linked with significant...
News
SGLT2 inhibitor ertugliflozin shows no CV death or renal benefit
- Author:
- Mitchel L. Zoler, PhD
Merck reports topline results from ertugliflozin’s FDA-mandated cardiovascular outcomes trial.
News
FDA reiterates hydroxychloroquine limitations for COVID-19
- Author:
- Mitchel L. Zoler, PhD
An FDA Safety Communication restates that hydroxychloroquine and chloroquine are only for hospitalized COVID-19 patients who can’t enter a trial...